Trilaciclib reshapes SCLC supportive care by protecting bone marrow from chemo, reducing anemia and thrombocytopenia, and improving treatment tolerance and quality of life.
Martin Dietrich, MD, PhD
Martin F. Dietrich, MD, PhD, is an assistant professor of internal medicine at the University of Central Florida College of Medicine and medical oncologist with Cancer Care Centers of Brevard and The US Oncology Network
Articles by Martin Dietrich, MD, PhD
Explore innovative strategies in small cell lung cancer treatment, focusing on bone marrow protection to enhance patient outcomes and treatment durability.
CDK4/6 Inhibition Preserves Multiple Cell Lines in SCLC
Published: | Updated:
Martin F. Dietrich, MD, PhD, discusses the use of the CDK4/6 inhibitor trilaciclib to address myelosuppression associated with chemotherapy in small cell lung cancer.
Challenges for Following NCCN Guidelines for MET Inhibitors in NSCLC
Published: | Updated:
Martin Dietrich, MD, PhD, discusses the National Comprehensive Cancer Network guidelines for using MET inhibitors in patients with non–small cell lung cancer and their impact on sequencing therapies.
The Relevance of MET Alterations to Targeted NSCLC Therapies
Published: | Updated:
Martin Dietrich, MD, PhD, discusses the role MET alterations play as oncogenic drivers of non–small cell lung cancer.
Latest Updated Articles
The Relevance of MET Alterations to Targeted NSCLC TherapiesPublished: November 25th 2021 | Updated: September 18th 2023
- Challenges for Following NCCN Guidelines for MET Inhibitors in NSCLC
Published: January 3rd 2022 | Updated: September 18th 2023
CDK4/6 Inhibition Preserves Multiple Cell Lines in SCLCPublished: December 10th 2025 | Updated: January 23rd 2026